On Friday, in his speech at the Fed's Jackson Hole Economic Policy Symposium, Chairman Jerome Powell signaled the first reduction in the benchmark interest rate since March 2020. The Fed fund rate is currently in the range of 5.25-5.5%, its highest level in 23 years. Although Powell refrained from announcing the time and the extent of the rate cut, Wall Street expects the first cut in the September FOMC meeting. A rate cut is likely to benefit small-cap stocks the most, aside from largecaps. At this stage, ...

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 0.9% over the past four weeks to close the last trading session at $8.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.90 indicates a potential upside of 60.9%. The average comprises four short-term price targets ranging from a low of $11 to a high of $16, with a standard deviation of $2.17. While the lowest estima ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Brainsway Ltd. Sponsored ADR (BWAY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Brainsway Ltd. Sponsored ADR is one of 1018 companies in the Medical ...

Have you been paying attention to shares of Brainsway Ltd. Sponsored ADR (BWAY) ? Shares have been on the move with the stock up 21.1% over the past month. The stock hit a new 52-week high of $8.28 in the previous session. Brainsway Ltd. Sponsored ADR has gained 21.5% since the start of the year compared to the 9.5% move for the Zacks Medical sector and the 8.4% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surpri ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the s ...

PM Images/DigitalVision via Getty Images BrainsWay (NASDAQ:BWAY) (OTCPK:BRSYF) reported strong earnings again in the second quarter, particularly from a margin perspective. This strength is particularly notable given Neuronetics (STIM) recent struggles. BrainsWay's revenue was up 28% YoY, and while growth is moderating, this is coming against increasingly difficult comparable periods. I previously suggested that BrainsWay's stock should continue to rerate higher as the company's profitable growth trajectory ...

Investors might want to bet on Brainsway Ltd. Sponsored ADR (BWAY) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earni ...

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $6.82, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $11.75 indicates a 72.3% upside potential. The average comprises four short-term price targets ranging from a low of $9 to a high of $15, with a standard deviation of $2.50. While the lowest estimate indicates an increase of 32% from the curren ...

财务数据和关键指标变化 - 第二季度收入为1000万美元,同比增长28% [7][15] - 毛利率为75%,较上年同期的73%有所提升 [15] - 第二季度实现净利润60万美元,上年同期为净亏损170万美元 [18] - 连续第四个季度实现正的经调整EBITDA和经营活动现金流 [17] - 截至6月30日,现金和短期存款余额为48.1亿美元,无债务 [19] 各条业务线数据和关键指标变化 - 前两个季度共出货114台Deep TMS系统,同比增长13%,累计安装量达1215台 [9] - OCD治疗适应症需求保持强劲,约50%的安装基础具备OCD治疗能力 [10] - 继续加强和拓展与大型机构和企业客户的合作伙伴关系 [10] 各个市场数据和关键指标变化 - 国际市场占比约20%,亚太地区尤其是印度、韩国、台湾、泰国需求强劲,欧洲如法国、意大利、西班牙也有很大需求 [22] - 6月宣布与加拿大一家大型专业分销商签署独家多年分销协议,首年订单11台Deep TMS系统,后续年度逐步增加 [11] 公司战略和发展方向及行业竞争 - 继续推进360系统在多个适应症的试点项目,相信这将成为未来主要技术之一 [24] - 正在与多家合作伙伴就成瘾症适应症的分销渠道进行洽谈 [24] - 通过自身渠道拓展和新适应症获批等方式,持续加大销售和营销投入以加速增长 [25][26] 管理层对经营环境和未来前景的评论 - 对下半年及全年业绩保持乐观,预计2024年全年收入将增长21%-25%至38.5-40亿美元 [8][19] - 盈利能力和现金流正面趋势将延续全年 [8][38] - 看好国内外市场需求持续增长,将继续加大投资以加快渠道拓展和新适应症开发 [26][44] 其他重要信息 - FDA批准Deep TMS系统适应症扩大至22-86岁MDD患者,这是TMS领域首次获得此类批准 [12] - 正在开展加速MDD治疗方案的临床试验,有望提高患者便利性 [13] 问答环节重要的提问和回答 问题1 **Steve Lichtman 提问** 国际市场占比及未来重点区域 [21] **Hadar Levy 回答** 国内外占比约80%/20%,亚太地区如印度、韩国、台湾、泰国需求强劲,欧洲如法国、意大利、西班牙也有很大需求 [22] 问题2 **Jeffery S. Cohen 提问** 加速MDD治疗方案的具体情况 [27][28] **Hadar Levy 回答** 从30天缩短至6天,每天多次治疗 [28] 问题3 **Unidentified Analyst 提问** 未来盈利能力及增长动力 [37][38][39][40] **Hadar Levy 回答** 计划保持盈利,通过大型企业客户拓展、OCD适应症需求增加、灵活的商业模式等推动持续增长 [38][39][40]

Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth Consecutive Quarter Raising Lower End of Full-Year 2024 Revenue Guidance to Range of $38.5 Million to $40 Million Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global lead ...